Skip to content

PCA-oxycodone after cardiac surgery; respiratory effects, and short and long term outcome

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515530-33-00
Acronym
2024-515530-33-00
Enrollment
100
Registered
2024-09-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease Aortic valve disease Mitral valve disease Tricuspidal valve disease or combination of the above

Brief summary

Nightly pulse oximetry desaturations: amount, depth, and time of recovery heir duration and respiratory rate. The connection of these changes to use of oxycodone PCA use.

Detailed description

Pain after cardiac surgery, morbidity, anxiety and depression, resilience, life satisfaction and heath related quality of life, Pain assessment daily with NRS at the hospital, Surgical complications with Clavien-Dindo classification, Pain outside hospital with Brief Pain Inventory (BPI)

Interventions

DRUGPanadol Forte 1000 mg tabletti
DRUGOxanest® 10 mg/ml injektionsvätska
DRUGlösning

Sponsors

Pohjois-Savon hyvinvointialue
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Nightly pulse oximetry desaturations: amount, depth, and time of recovery heir duration and respiratory rate. The connection of these changes to use of oxycodone PCA use.

Secondary

MeasureTime frame
Pain after cardiac surgery, morbidity, anxiety and depression, resilience, life satisfaction and heath related quality of life, Pain assessment daily with NRS at the hospital, Surgical complications with Clavien-Dindo classification, Pain outside hospital with Brief Pain Inventory (BPI)

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026